

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Yestar Healthcare Holdings Company Limited

巨星醫療控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2393)

ANNOUNCEMENT

PROFIT WARNING

This announcement is made by Yestar Healthcare Holdings Company Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited and the Inside Information Provisions under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The board (the “**Board**”) of directors (the “**Directors**”) of the Company hereby informs the shareholders and potential investors of the Company that, based on the currently available unaudited management accounts of the Group and the preliminary assessment by the Company’s management, the Company is expected to record an unaudited consolidated net loss of the Group of approximately RMB180.2 million and an unaudited consolidated net loss attributable to the owners of the parent of approximately RMB161.5 million for the six months ended 30 June 2022 (“**the Interim Period 2022**”) as compared to an unaudited consolidated net profit of the Group of approximately RMB120.9 million and an unaudited consolidated net profit attributable to the owners of the parent of approximately RMB111.9 million for the six months ended 30 June 2021.

The expected turnaround from net profit to net loss of the Group for the Interim Period 2022 is primarily attributed to the significant decrease in revenue of our medical business, which was due to (i) the drop in demand for medical check up in hospitals and decline in mobility of people across China due to its strict travel restriction policies as well as complete or partial lockdown of various major cities or areas including Shanghai and Beijing; and (ii) an impairment loss on intangible assets of the Group.

The Group is still in the process of finalizing its unaudited consolidated results for the Interim Period 2022. The information contained in this announcement is only a preliminary assessment by the Board based on the unaudited management accounts for the Interim Period 2022 and the information currently available to the Board, which may be subject to further adjustments after further internal review by the Board. Details of the unaudited financial performance of the Group will be contained in the interim results announcement of the Group for the Interim Period 2022, which is expected to be published on 24 August 2022.

Shareholders of the Company and potential investors are advised to exercise caution when dealing in the shares of the Company.

By Order of the Board
Yestar Healthcare Holdings Company Limited
Hartono James
Chairman, CEO and Executive Director

12 August 2022

As at the date of this announcement, the executive Directors are Mr. Hartono James, Ms. Wang Hong, Ms. Liao Changxiang and Mr. Liang Junxiong; and the independent non-executive Directors are Dr. Hu Yiming, Mr. Zeng Jinsong and Mr. Sutikno Liky.